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were signiﬁcantly lower compared to human insulin only patients
($20,709, p < 0.001) and those receiving both analog and human
insulins ($28,679, p < 0.001). Inpatient visits, length of stay,
emergency visits, and clinic visits were also signiﬁcantly lower
(p < 0.001) for analog-only patients. Hypoglycemia-related costs
and utilization and overall diabetes-related utilization followed
the same patterns. CONCLUSION: Patients receiving only
analog insulin had higher insulin costs but lower post-index total
health care costs and utilization, whether all-cause or diabetes-
related, compared to patients receiving human insulin or a com-
bination of analog and human insulins.
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OBJECTIVE: Anemia is a well known complication associated
with CKD. However, there are little data regarding its association
with hospitalizations. The purpose of this study was to investi-
gate whether anemia is associated with increased hospitalization
costs in patients with diabetes and chronic kidney disease (CKD).
METHODS: An analysis of medical claims and laboratory data
between January 2000 and February 2006 from over 45 health
plans contributing to the Ingenix Impact National Managed Care
Database was conducted. Inclusion criteria were 2 hemoglobin
(Hb) values, 2 claims (within a 90-day period) for diabetes
mellitus preceding 1 claim for CKD and 2 glomerular ﬁltra-
tion rate values of <60 mL/min/1.73 m2, and not yet on dialysis.
Patients were excluded if they had cancer or lupus, received
organ transplantation or chemotherapy, or were treated for
anemia with an erythropoiesis-stimulating agent or blood trans-
fusions. An open-cohort design was used to classify patients
into observation periods of anemia (Hb < 11 g/dL), within the
K/DOQI treatment recommendations, and non-anemia, which
allowed for changes in anemia status over time. Both univariate
and multivariate analyses were conducted to compare periods of
anemia and non-anemia for average yearly hospitalization costs.
RESULTS: A total of 708 patients with diabetes and CKD
formed the study population. Mean age was 65 years; 44%
women. Anemia was associated with a signiﬁcant increase in
hospitalization costs, with an unadjusted incremental yearly cost
of $17,072 (anemia: $25,342; non-anemia: $8270; p < .001)
relative to non-anemia. The majority of hospitalizations (57%)
were related to cardiovascular disease, with anemia increasing
the cost of cardiovascular-hospitalizations by $8647 (anemia:
$13,723; non-anemia: $5076; p < .001). After controlling for
covariates, anemia remained signiﬁcantly associated with a hos-
pitalization cost increase. CONCLUSION: The current study
based on real-life practice data demonstrated that anemia in
patients with diabetes and CKD was associated with a signiﬁcant
increase in hospitalization costs.
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OBJECTIVE: To measure the effects of a pharmacist-run medi-
cation management program on medication adherence, glycemic
control, and total health care expenditures. METHODS: Scott
& White Health Plan (SWHP) claims data were evaluated to
identify high-risk diabetics aged 18–63 years, deﬁned as those
who demonstrate poor glycemic control (HbA1c >7.5%) and
utilized >$600 of prescription medications the year prior to
study enrollment. A control group was identiﬁed who met the
same inclusion criteria, but who were not invited to the program
due to geographic constraints. Medical utilization costs were
analyzed beginning one year prior to study enrollment and
included inpatient, outpatient, emergency department, and pre-
scription costs. Health system charges, standardized to 2006
dollars, were used as a surrogate for costs. Intervention costs
were estimated from pharmacists’ wage rates. Medication adher-
ence was calculated as medication possession ratio (MPR) of
oral antidiabetic agents. HbA1c results were analyzed to deter-
mine glycemic control. RESULTS: Analysis of 46 subjects and
their matched controls one year after program implementation
showed positive trends, although none of the results were sta-
tistically signiﬁcant. The mean MPR for the intervention group
increased from 0.69 to 0.79, while there was no change from a
baseline of 0.64 for controls [p = 0.24]. Intervention patients
demonstrated a greater improvement (9.5% to 8.2%) in HbA1c
than controls (9.5% to 8.7%) [p = 0.15]. Although total
monthly health care costs increased in both the intervention
($1448 to $1756; difference = $308  $2016) and control
groups ($1089 to $1745; difference = $656  $2641) [p = 0.46],
the increase was lower in the intervention group. CONCLU-
SION: Patients in the intervention group trended toward better
medication adherence and a greater decline in HbA1c than con-
trols. We expect the trend of cost savings will continue and
strengthen in the future due to long-term beneﬁts associated with
sustained glycemic control.
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OBJECTIVE: Patient and provider “psychological insulin resis-
tance” can contribute to a delay in initiation of insulin therapy
in patients with type 2 diabetes (T2DM). Consequently, by the
time patients initiate insulin, complications may have already
developed. If patients initiate insulin but therapy is not intensi-
ﬁed to reach glycemic goal (HbA1c 7%), the ability to prevent
or delay complications may be compromised. The objective of
this study was to determine differences in the incidence of com-
plications of diabetes between patients with HbA1c <7% and
those with HbA1c 7%. METHODS: US health claims and
clinical laboratory data from 2003–2005 were used to identify
and stratify patients by mean HbA1c (controlled 7% vs. sub-
optimally controlled 7%) for analysis. Cohort was limited to
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T2DM patients on insulin-only regimens with at least one
HbA1c value in the database and six months continuous eligi-
bility pre-post HbA1c index. Data on HbA1c, insulin regimen,
complications and demographic characteristics of all patients
were analyzed using descriptive statistics. RESULTS: Of 689
patients, 29% had HbA1c 7% (mean age 52 years; female 40%;
mean HbA1c 5.9%; basal-only 73%; basal-bolus 25%) while
71% had HbA1c 7% (mean age 51 years; female 41%; mean
HbA1c 9.3%; basal-only insulin 63%; basal-bolus insulin
34%). The nature and incidence of microvascular complications
in the two groups were: diabetic foot complications 2% and 6%
(p < 0.05), neuropathy 13% and 9%, retinopathy 9% and
13%, kidney disease 5% and 7% for patients with HbA1c <7%
and 7%, respectively. CONCLUSION: A sizable proportion
of T2DM patients were uncontrolled on their current insulin
regimen. This may reﬂect undue delay in insulin initiation and
intensiﬁcation by patients and providers. Moreover, a consider-
able proportion of patients at goal show signs of complications,
signifying the urgency of earlier insulin initiation and more
aggressive intensiﬁcation to ameliorate current sub-optimal gly-
cemic control.
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OBJECTIVE: To systematically review the literature and
published recommendations from four Health Technology
Assessment Agencies (HTAAs) in order to report what may
have contributed to the dearth of reimbursement of non-
injectable insulins. METHODS: Two independent researchers
systematically reviewed the published literature from 2003–
2007 using the MEDLINE, EMBASE, and Cochrane databases.
Publications of human trials involving non-injectable insulins
reported in any language were included. Keywords such as
Insulin, Oral OR Inhalation OR Aerosols OR Mist OR Spray
OR Sublingual OR Nebulizers OR Vaporizers OR Intranasal
OR Dermal OR Buccal with the indication of Diabetes Mellitus
Type 1 OR Diabetes Mellitus Type 2 were used. Clinical trials,
with at least one intervention being a non-injectable insulin,
were included. Exclusion criteria included inappropriate
research design, outcomes not reported and/or not extractable.
Listing decisions posted on the websites of the National Insti-
tute for Health and Clinical Excellence in the UK, the Scottish
Medicines Consortium, the Institute for Quality and Efﬁciency
in Health Care in Germany, and the Common Drug Review in
Canada were reviewed. RESULTS: Of 233 identiﬁed citations,
20 articles were included for full text review. Reported out-
comes included standard clinical efﬁcacy measures (e.g., post-
prandial glucose levels, HbA1c reduction) and tolerability. Few
articles (N = 3) reported outcomes such as patient preference
for treatment, general health-related quality of life, ﬁnal health
outcomes, and/or satisfaction. No studies were speciﬁcally
designed for reimbursement purposes. There was a paucity of
utility measures, the lack of which was the main criticism by
the HTAAs leading to either “not to list” or very restricted
listing recommendations. Other HTAA comments were the use
of secondary versus primary clinical outcomes and the absence
of adherence information. CONCLUSION: Clinical studies for
non-injectable insulins do not include adequate information
and/or outcomes that are required by decision makers for reim-
bursement recommendations.
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OBJECTIVE: To describe ﬁrst and second-line use of antidiabetic
drugs for management of type 2 diabetes in Italy, and to identify
potential predictors associated with the use of antihyperglycemic
drugs. METHODS: Primary care data were obtained from
400 Italian General Practitioners (GPs) providing information to
the Health Search/Thales Database (HSD). All patients with a
doctor-diagnosis of type 2 diabetes during the years 1996–2006
were selected. First and second-line drug therapy episodes were
evaluated by assessing the sequential fulﬁlment of prescriptions
of a particular antihyperglycemic drug class (or combination),
which followed the diabetes diagnosis. A sub-sample of diabetic
patients, with a registered diagnosis until the December 31, 2003
was also selected to evaluate the time-dependant clinical and
demographic characteristics associated with the use of different
antihyperglycemic drugs across the years 2004–2006. RESULTS:
A total of 19,561 diabetic patients had diabetes drug therapy
episodes between 1996 and 2006. Monotherapy with metformin
increased (from 4.1% in 1996 to 44.8% in 2006), while mono-
therapy with sulfonylureas decreased over time (from 32.7% to
23.9%) as ﬁrst line therapy. Thiazolidinedione (from 0.3% to
0.6%)and other oral antihyperglycemics (from 0.7% to 4.3%)
also raised over the period. Second-line drug therapy episodes
shown the same trend during study period with a substantial
increased use of thiazolidinedione (from 2.5% to 3.8%). As
regards prevalent patients characteristics, hypercholesteremia
and obesity were signiﬁcantly associated with the use of thiazo-
lidinediones while coronary artery disease, chronic renal and
hepatic failure were associated with insulin use. CONCLUSION:
Antihyperglycemic prescription patterns in Italy dramatically
changed from 1996 to 2006 with increased use of metformin and
decreased use of sulfonylureas. The introduction of thiazo-
lidinediones to the marketplace seems not change the manage-
ment of diabetes mellitus as ﬁrst line-treatment, although this
drug class is preferred in chronic patients particularly affected by
hypercholesteremia and obesity.
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OBJECTIVE: To proﬁle physician prescription Behavior for
patients with type 2 diabetes in a managed care setting.
METHODS: We used a retrospective cohort study design with
patient-de-identiﬁed national health claims databases (70+
million unique lives from January 1, 2098 through December
31, 2004). Patients with T2D were identiﬁed based on ICD-
9-CM codes, and were grouped into 6 cohorts (general practi-
tioner, other primary care specialist, internist, endocrinologist,
cardiologist, and other specialties) based on the practice spe-
cialty of physicians who prescribed the ﬁrst insulin for their
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